Eli Lilly and Company / LLY

Equity | Generated Nov 6, 2026 11:31 PM EST

Current price	Daily move	Bid / Ask	Previous close
$1,357.00	-7.73 -0.57%	-/-	$1,364.73

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Nov 6, 2026 11:31 PM EST**

JW Intelligence Report

Complete | 3 of 3 sections | Nov 6, 2026 6:50 PM EST

JW Rank	Rank label	Confidence	IV percentile
72.5 / 100	Constructive	high	30 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,345.00	$1,425.00	$1,315.00	66 / 100

Options stance	**bullish**
Tail-risk safety	**56 / 100**
JW Rank data coverage / as of	**100.0% | Nov 6, 2026 6:50 PM EST**

Key insight

Lilly Option Market Prices in Continued Growth and Positive Sentiment

Market read

The US option market for LLY reflects a bullish outlook, driven by strong earnings results, positive analyst sentiment, and continued demand for its diabetes drugs. The implied volatility is elevated but not extreme, suggesting investors anticipate further upside potential.

Strategy context

The option chain shows a slight skew towards calls, indicating a preference for upside potential. However, the term structure is relatively flat, suggesting that investors are not overly concerned about near-term volatility.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Nov 6, 2026 2:20 PM EST**

Short-term scenario

Cautious tactical long only on a pullback over 1-3 weeks; do not chase strength after the post-earnings run. Prefer support near today's low; stand aside if that area fails. This is not advice. Uncertainty is high because of valuation, oral competition, and consolidation after a sharp rally.

Three-month outlook

Constructive but not a high-conviction breakout. Obesity and incretin demand, the raised 2026 outlook, manufacturing expansion, and pipeline items such as retatrutide can support a drift toward the low-to-mid $1,400s if volume keeps outrunning price cuts. A reasonable base case is modest upside toward consensus targets near $1,430-$1,500; moves toward the higher post-earnings targets need better oral and ex-US execution. Downside risk rises if Foundayo continues to lag Novo's pill, net prices fall faster than volume grows, or the market de-rates premium healthcare multiples. Uncertainty is material over three months and depends more on pricing, competition, and macro conditions than on today's Hims headline.

Market sentiment

Post-earnings discussion was strongly positive on the beat, guidance raise, and record-high reaction. More recent posts often frame LLY as a defensive growth holding versus AI-related volatility, with some traders citing accumulation. Sentiment is net constructive, but valuation, net-price erosion, and Novo's oral lead are recurring caveats; one sentiment snapshot described modestly positive buzz with bulls focused on demand and bears on price. Today's Hims deal drew more excitement for HIMS than for LLY. Uncertainty: X is noisy, includes promotional posts, and is not a reliable sample of institutional positioning.

Supporting evidence


Strong post-earnings performance with the stock rallying after exceeding revenue and EPS expectations. | Raised FY2026 revenue guidance driven by strong sales of Mounjaro and Zepbound. | Analyst consensus remains Buy with price targets clustering near $1,430-$1,442. | Positive sentiment from market participants citing demand for Lilly's products and a defensive growth narrative.

Risk watch

Valuation remains elevated, with a trailing P/E ratio in the low 40s and a forward multiple closer to 30x. | Competition from Novo Nordisk's oral Wegovy could pressure Foundayo sales.

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Above MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | neutral | MACD decelerating**
Trend signal	**STRONG BULL**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**53.85 / 61.14 / 61.50**
RSI velocity	**-4.89**
MACD line / signal / histogram	**52.92 / - / 47.83**
MACD acceleration	**-1.16**
Stochastic K / D	**64.34 / 74.53**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Accumulation bias**
Institutional flow	**12.53**
20-day MVWAP	**$1,329.85**
Price vs 20-day MVWAP	**+2.04%**
Daily reference VWAP	**$1,354.83**
Price vs daily reference	**+0.16%**
Volume	**2.48M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**9.99**
20-day / 200-day SMA	**$1,301.95 / $1,099.64**
Bollinger range	**$1,146.41 - $1,457.50**
Bollinger position	**0.667**

Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
32 / 100	38 / 100	120.76	149.37

Market regime	**Calm**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**flat**
Term slope	**+0.25 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 6, 2026 2:55 PM EST**
Options data quality	**Coverage 100.0%**

Option term structure

ATM implied-volatility curve by days to expiration



Upward-sloping ATM volatility term structure


EXPIRATION	DTE	ATM IV	STATE
2026-11-13	7	33.3%	-
2026-11-20	14	33.9%	-
2026-11-27	21	33.6%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference


Short $1,315.00 | Long $1,310.00 | Width $5.00 | Net credit $0.92



Max profit $92.00 | Max loss -$408.00 | Break-even $1,314.08 | Per contract at expiry

Bear Call Spread reference

Short $1,405.00 | Long $1,410.00 | Width $5.00 | Net credit $1.15



Max profit $115.00 | Max loss -$385.00 | Break-even $1,406.15 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**moderate**
Event IV premium	**-0.56**
VIX	**24.77**
VVIX	**120.76**
SKEW index	**149.37**
Observation confidence	**high**
Option quote quality	**reliable**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts observed	**108**
Contracts with quotes	**108**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The US option market for LLY reflects a bullish outlook, driven by strong earnings results, positive analyst sentiment, and continued demand for its diabetes drugs. The implied volatility is elevated but not extreme, suggesting investors anticipate further upside potential.

Options context

Lilly Option Market Prices in Continued Growth and Positive Sentiment

Wheel context

The option chain shows a slight skew towards calls, indicating a preference for upside potential. However, the term structure is relatively flat, suggesting that investors are not overly concerned about near-term volatility.

Observed evidence

Strong post-earnings performance with the stock rallying after exceeding revenue and EPS expectations. | Raised FY2026 revenue guidance driven by strong sales of Mounjaro and Zepbound. | Analyst consensus remains Buy with price targets clustering near $1,430-$1,442. | Positive sentiment from market participants citing demand for Lilly's products and a defensive growth narrative.

Principal risks to monitor

Valuation remains elevated, with a trailing P/E ratio in the low 40s and a forward multiple closer to 30x. | Competition from Novo Nordisk's oral Wegovy could pressure Foundayo sales.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.28T	**48.37**
ROE	Revenue growth
83.7%	**31.7%**
EPS growth	Operating margin
49.3%	**40.3%**
Net profit margin	Gross margin
31.9%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.37**

52-week range

$850.51 - $1,449.68

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
940.75M	**56.4%**
Book value per share	Revenue per share
$42.79	**$96.78**

Website	lilly.com

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Nov 4, 2026 3:45 PM EST

Covered Call | 2026-11-06

At signal $1,422.74 | Current $1,357.00

SHORT **Option $1,425.00 B $14.30 / A $14.95**

Conservative | CR $14.63

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$47.35**
ATR as % of price	**3.5%**
Volatility environment	**medium**
Current IV	**32.7%**
IV rank	**27 / 100**
IV percentile	**30 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Nov 6, 2026 6:31 PM EST**

Technical health and risk radar

Derived indicator health and event context

Overall health	**83 / 100**
Trend health	**92 / 100**
Momentum health	**89 / 100**
Volatility health	**58 / 100**
Structure health	**83 / 100**
Earnings risk / date	**unknown | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,301.95 / $1,214.25 / $1,099.64**
EMA (9 / 21)	**$1,361.57 / $1,310.82**
Bollinger upper / middle / lower	**$1,457.50 / $1,301.95 / $1,146.41**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.667**
True high / low	**$1,377.28 / $1,333.22**
5-day true high / low	**$1,453.00 / $1,333.22**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	9.986	**-**
SMA50	3.584	**-**
MVWAP20	12.526	**-**
MACD	-1.156	**-**
RSI	-4.889	**-**
Volume	314220.000	**-**
ATR	0.955	**-**
T1	-	**56.53 / 1324.24 / 1453.00 / 1364.73**
T2	-	**59.23 / 1307.09 / 1445.96 / 1401.59**
T3	-	**56.38 / 1292.28 / 1437.00 / 1393.47**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,360.85**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 6, 2026 2:55 PM EST**
Options data coverage	**100.0%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX RISING**
Front expiration / DTE	**2026-11-13 | 7 DTE**
Front at-the-money IV	**33.3%**
25-delta skew	**3.40**
Put / Call 25-delta	**$1,315.00 Delta -0.240 / $1,405.00 Delta 0.248**
Median option bid/ask spread	**6.5%**
Bid/ask spread	**-**
Contracts observed / quoted	**108 / 108**

Price context

Last Price: 1,360.85 | Bid: 1,360.75 | Ask: 1,361.09 | Previous Close: 1,364.73 | Change: -3.88 | Daily change: -0.28% | Update Time: 2026-11-06T14:55:05.898791-05:00 | Latest History Date: 2026-11-06 | Latest History Price: 1,360.90

Historical context

Trading-day sample: 60 sessions | First Date: 2026-08-14 | Latest Date: 2026-11-06 | Latest Price: 1,360.90 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 33.65% | Iv Rank: 31.50 | Iv Percentile: 37.85 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Nov 6, 2026 11:31 PM EST. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**